Hoffman leaves Microsoft board for Manas AI drug discovery
Reid Hoffman, LinkedIn co-founder and a Microsoft board member since 2017, says he will not seek re-election at Microsoft’s 2026 annual shareholder meeting. The move is to focus full-time on Manas AI, an AI drug discovery startup co-founded with oncologist Siddhartha Mukherjee.
Manas AI launched in early 2025 with an initial focus on aggressive cancers, including breast cancer, prostate cancer, and lymphoma. The company raised about $24.6M in its first funding round in February 2025, with reported total capital exceeding $50M.
Hoffman’s decision follows a pattern of stepping back from high-profile board roles to manage conflicts and concentrate on priority projects. In March 2023, he resigned from OpenAI’s board, citing the need to avoid conflicts of interest amid his broader AI investments and as Microsoft deepened its partnership with OpenAI.
Keywords: Manas AI, AI drug discovery. This shift signals continued investor and executive attention to AI-driven biotech pipelines, rather than direct changes to crypto markets.
Neutral
This is a tech-sector corporate governance and startup-funding headline (Hoffman leaving the Microsoft board to focus on Manas AI). It does not introduce any explicit crypto protocol changes, token listings, regulatory actions, or macro shocks tied directly to BTC/ETH or major crypto infrastructure.
For traders, the closest “market mechanism” is sentiment: high-profile AI executives and capital flowing into AI/biotech can marginally boost risk appetite for tech-heavy narratives, but there is no clear linkage to crypto cash flows. Historically, board reshuffles or startup funding announcements without token-specific catalysts tend to produce little to no sustained price impact—any reaction is usually short-lived and driven by broader tech sentiment rather than fundamentals of crypto assets.